Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance
- 8 October 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (5), 986-1001
- https://doi.org/10.1111/j.1476-5381.2010.00824.x
Abstract
The use of opioids in treating pain is limited due to significant side effects including somnolence, constipation, analgesic tolerance, addiction and respiratory depression. Pre-clinical studies have shown that neurokinin 1 (NK(1) ) receptor antagonists block opioid-induced antinociceptive tolerance and may inhibit opioid-induced rewarding behaviours. Here, we have characterized a bifunctional peptide with both opioid agonist and NK(1) antagonist pharmacophores in a rodent model of neuropathic pain. Rats were evaluated for behavioural responses to both tactile and thermal stimuli in either an uninjured, sham- or nerve-injured state. TY005 (Tyr-DAla-Gly-Phe-Met-Pro-Leu-Trp-O-3,5-Bn(CF(3) )(2) ) was delivered spinally or systemically to assess the antinociceptive effects after acute exposure. Motor skills were evaluated using the rotarod test to determine potential sedative effects. Spinal TY005 was given chronically to sham- or nerve-injured animals to determine the development of tolerance. Bolus injections of TY005 produced dose-dependent antinociception in non-injured animals and alleviated nerve injury-induced thermal and tactile hypersensitivities (i.e. antihyperalgesia) more effectively than morphine. Sedative effects were not evident from the rotarod test at doses that were antihyperalgesic, nor at doses threefold higher. Repeated administration of TY005 did not lead to the development of antihyperalgesic tolerance or alter sensory thresholds. Collectively, the data suggest that opioid agonist/NK(1) antagonist bifunctional peptides represent a promising novel approach to the management of chronic pain without the development of tolerance, reducing the need for escalation of doses and unwanted side effects associated with opiates alone.This publication has 55 references indexed in Scilit:
- Pathophysiology of PainMedical Clinics of North America, 2007
- Disinhibition Opens the Gate to Pathological Pain Signaling in Superficial Neurokinin 1 Receptor-Expressing Neurons in Rat Spinal CordJournal of Neuroscience, 2006
- Activation of NK1 receptor of trigeminal root ganglion via substance P paracrine mechanism contributes to the mechanical allodynia in the temporomandibular joint inflammation in ratsPain, 2005
- Role of NK-1 neurotransmission in opioid-induced hyperalgesiaPain, 2005
- Resting and Evoked Spinal Substance P Release during Chronic Intrathecal Morphine Infusion: Parallels with Tolerance and DependenceThe Journal of pharmacology and experimental therapeutics, 2005
- Intrathecal Morphine Reduces Allodynia after Peripheral Nerve Injury in Rats via Activation of a Spinal A1 Adenosine ReceptorAnesthesiology, 2005
- Underlying mechanisms of pronociceptive consequences of prolonged morphine exposurePeptide Science, 2005
- Opioid activity of sendide, a tachykinin NK1 receptor antagonistEuropean Journal of Pharmacology, 1999
- Involvement of spinal cord δ opiate receptors in the antinociception of gestation and its hormonal simulationBrain Research, 1997
- The effects of pain on opioid tolerance: how do we resolve the controversy?1996